抑制MAFB与PI3K/AKT信号通路治疗伴多中心腕跗骨溶解的遗传性FSGS
本研究利用携带MCTO突变的基因编辑小鼠模型,发现MAFB蛋白累积导致FSGS,且IGF-1介导的PI3K/AKT通路显著上调;伊马替尼抑制该通路可显著降低尿白蛋白水平。
要点
- MCTO突变导致MAFB蛋白累积并引起FSGS。
- 降低MAFB水平可避免白蛋白尿和肾脏组织学异常。
- 伊马替尼靶向PI3K/AKT通路可改善白蛋白尿。
核心结论
- MCTO突变导致MAFB蛋白累积并引发FSGS,靶向MAFB/IGF-1/PI3K/AKT信号可能为MCTO相关肾病提供新治疗。
研究设计与样本
- 使用携带MCTO突变的基因编辑小鼠模型(MafbMCTO/MCTO小鼠)探索MAFB的作用。
主要发现
- MafbMCTO/MCTO小鼠表现为FSGS,与MCTO患者表现一致。
- MCTO突变导致MAFB蛋白累积。
- 杂合MafbMCTO/-小鼠(降低MAFB水平)无白蛋白尿及肾脏组织学异常。
- RNA-seq显示MafbMCTO/MCTO小鼠肾小球中IGF-1介导的PI3K/AKT信号通路显著上调。
- 伊马替尼治疗使MafbMCTO/MCTO小鼠尿白蛋白水平较对照组显著下降。
临床怎么用
- 对于MCTO相关肾病,可考虑靶向MAFB/IGF-1/PI3K/AKT信号通路作为潜在治疗策略。
局限性
- 研究基于小鼠模型,结果需进一步在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Multicentric carpotarsal osteolysis, a rare disorder, causes progressive osteolysis and kidney failure because of v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene mutations. A genome-edited mouse model carrying the multicentric carpotarsal osteolysis mutation was used to obtain a deeper understanding of this rare disease. Targeting MAFB/IGF-1/PI3K/AKT signaling may provide new treatments for multicentric carpotarsal osteolysis-related nephropathy. BACKGROUND: Multicentric carpotarsal osteolysis (MCTO) is a rare condition characterized by progressive osteolysis and often kidney failure. It is caused by autosomal dominant mutations in the transcription factor v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B ( MAFB ). METHODS: Given the absence of efficacious therapeutic interventions for MCTO and the obscurity of its pathophysiologic mechanisms, we used mice with the MCTO mutation ( MafbMCTO/MCTO mice) to explore the role of MAFB. RESULTS: MafbMCTO/MCTO mice displayed FSGS, mirroring the manifestations seen in patients with MCTO. These mice showed that the MCTO mutation leads to the accumulation of MAFB protein. Heterozygous MafbMCTO/- mice, generated by crossbreeding to reduce MAFB levels, neither exhibited albuminuria nor showed any histologic abnormalities in the kidney, suggesting that excess MAFB was detrimental. We subsequently conducted RNA-seq on the glomeruli from MafbMCTO/MCTO mice and detected pronounced upregulation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway through IGF-1. Given that receptor tyrosine kinases activate PI3K/AKT, we treated MafbMCTO/MCTO mice with the inhibitor imatinib. This led to a significant decline in urinary albumin levels compared with the control group. CONCLUSIONS: Our findings demonstrate that the MCTO mutation resulted in MAFB protein accumulation and led to the development of FSGS in mice.
引用
- Usui T, Ishibashi S, Tanaka R, et al. Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis. J Am Soc Nephrol. 2026. PMID: 41842942. doi:10.1681/ASN.0000001060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。